As Biotechnology companies, Molecular Templates Inc. (NASDAQ:MTEM) and CRISPR Therapeutics AG (NASDAQ:CRSP) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Molecular Templates Inc.||9||0.00||20.78M||-0.90||0.00|
|CRISPR Therapeutics AG||54||0.00||34.37M||-3.74||0.00|
Table 1 highlights Molecular Templates Inc. and CRISPR Therapeutics AG’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 hightlights the return on assets, return on equity and net margins of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|Molecular Templates Inc.||229,106,945.98%||-30.4%||-21.7%|
|CRISPR Therapeutics AG||64,051,434.96%||-50.9%||-39.8%|
The Current Ratio and a Quick Ratio of Molecular Templates Inc. are 3.2 and 3.2. Competitively, CRISPR Therapeutics AG has 15.8 and 15.8 for Current and Quick Ratio. CRISPR Therapeutics AG’s better ability to pay short and long-term obligations than Molecular Templates Inc.
The following table given below contains the ratings and recommendations for Molecular Templates Inc. and CRISPR Therapeutics AG.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Molecular Templates Inc.||0||0||0||0.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Meanwhile, CRISPR Therapeutics AG’s average target price is $66.5, while its potential downside is -5.95%.
Institutional and Insider Ownership
Molecular Templates Inc. and CRISPR Therapeutics AG has shares held by institutional investors as follows: 72.2% and 50%. 12.75% are Molecular Templates Inc.’s share held by insiders. On the other hand, insiders held about 2% of CRISPR Therapeutics AG’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Molecular Templates Inc.||-8.75%||-22.34%||-8.88%||47.64%||32.46%||62.62%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Molecular Templates Inc.’s stock price has smaller growth than CRISPR Therapeutics AG.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.